company background image
AVE

Avecho Biotechnology ASX:AVE Stock Report

Last Price

AU$0.013

Market Cap

AU$22.1m

7D

0%

1Y

-18.8%

Updated

12 Aug, 2022

Data

Company Financials
AVE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

AVE Stock Overview

Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries.

Avecho Biotechnology Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Avecho Biotechnology
Historical stock prices
Current Share PriceAU$0.013
52 Week HighAU$0.023
52 Week LowAU$0.012
Beta1.96
1 Month Change8.33%
3 Month Change-27.78%
1 Year Change-18.75%
3 Year Change225.00%
5 Year Change-31.58%
Change since IPO-97.29%

Recent News & Updates

May 31
Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

AVEAU PharmaceuticalsAU Market
7D0%3.6%1.1%
1Y-18.8%-11.3%-8.1%

Return vs Industry: AVE underperformed the Australian Pharmaceuticals industry which returned -11.3% over the past year.

Return vs Market: AVE underperformed the Australian Market which returned -8.1% over the past year.

Price Volatility

Is AVE's price volatile compared to industry and market?
AVE volatility
AVE Average Weekly Movement15.7%
Pharmaceuticals Industry Average Movement12.5%
Market Average Movement10.6%
10% most volatile stocks in AU Market18.0%
10% least volatile stocks in AU Market4.6%

Stable Share Price: AVE is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: AVE's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1992n/aPaul Gavinhttps://avecho.com.au

Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company’s human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches.

Avecho Biotechnology Limited Fundamentals Summary

How do Avecho Biotechnology's earnings and revenue compare to its market cap?
AVE fundamental statistics
Market CapAU$22.05m
Earnings (TTM)-AU$3.42m
Revenue (TTM)AU$793.60k

30.2x

P/S Ratio

-7.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVE income statement (TTM)
RevenueAU$793.60k
Cost of RevenueAU$285.66k
Gross ProfitAU$507.94k
Other ExpensesAU$3.92m
Earnings-AU$3.42m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0019
Gross Margin64.00%
Net Profit Margin-430.46%
Debt/Equity Ratio0%

How did AVE perform over the long term?

See historical performance and comparison